{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.3","upperLimit":"70.0","value":"58.5"},{"groupId":"OG001","lowerLimit":"30.5","upperLimit":"53.8","value":"41.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"DCR is defined as the percentage of participants who achieved a CR or PR or stable disease (SD) using RECIST (v1.1) as assessed by the investigator.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 2 OC: Niraparib 200mg + Pembrolizumab"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 2 TNBC: Niraparib 200mg + Pembrolizumab"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set. Only those participants with data available at specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 40 weeks","title":"Phase 2: Disease Control Rate (DCR) as Measured by RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}